Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 24, 2024; 15(8): 987-991
Published online Aug 24, 2024. doi: 10.5306/wjco.v15.i8.987
Circulating tumor cells in pancreatic cancer: The prognostic impact in surgical patients
Macarena Teja, Abrahams Ocanto, Felipe Couñago
Macarena Teja, Abrahams Ocanto, Felipe Couñago, Department of Radiation Oncology, GenesisCare-San Francisco de Asís University Hospital, Madrid 28002, Spain
Macarena Teja, Abrahams Ocanto, Felipe Couñago, Department of Radiation Oncology, GenesisCare-Vithas La Milagrosa University Hospital, Madrid 28010, Spain
Felipe Couñago, National Director, GenesisCare Spain, Madrid 28043, Spain
Author contributions: Teja M contributed to the discussion and design of the manuscript; Teja M, Ocanto A and Couñago F contributed to writing and editing the manuscript, review of the literature, and designed the overall concept and outline of the manuscript; All authors contributed to this paper.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Macarena Teja, MD, Attending Doctor, Department of Radiation Oncology, GenesisCare-San Francisco de Asís University Hospital, C/Joaquín Costa 28, Madrid 28002, Spain. macarena.teja@genesiscare.es
Received: May 15, 2024
Revised: June 27, 2024
Accepted: July 3, 2024
Published online: August 24, 2024
Processing time: 92 Days and 22.1 Hours
Core Tip

Core Tip: Circulating tumor cells (CTCs) are showing promising results in the diagnosis and monitoring of oncological patients. When detected before or during surgery in early-stage pancreatic cancer patients, a correlation with decreased overall survival, relapse-free, disease-free and progression-free survival has been demonstrated. However, there is an absence of homogeneity between the isolation platforms used that makes it necessary to compare them in order to introduce CTCs detection into clinical practice of pancreatic cancer.